Head-twitch response

The head-twitch response (HTR) is a rapid, side-to-side rotational head movement that mice — and less reliably rats — make after receiving a compound that activates the 5-HT₂A serotonin receptor. Each discrete twitch is counted over a fixed observation window, typically twenty to thirty minutes after administration, giving researchers a quantitative, in-vivo measure of receptor engagement.

The assay became the standard preclinical screen for hallucinogenic potential because classical serotonergic psychedelics — including LSD, psilocin, DMT, and mescaline — reliably produce it, while non-serotonergic psychoactive compounds generally do not. Its receptor basis is confirmed by pre-treating the animal with a selective 5-HT₂A antagonist such as ketanserin or MDL 100,907: this abolishes the twitches, demonstrating that the response is receptor-mediated rather than a non-specific motor effect.

What this design can establish

A well-run HTR experiment can establish that a compound activates 5-HT₂A receptors in a living animal — not merely in isolated tissue, but under conditions where the drug must be absorbed, distributed, and metabolised normally. Dose-response curves derived from twitch counts support potency comparisons between compounds and can distinguish full from partial receptor agonists.

Because the HTR tracks reliably with known classical psychedelics, a positive result is meaningful evidence that a novel compound shares their receptor mechanism. Within a chemical series, HTR data support structure-activity relationship conclusions — identifying which structural modifications increase, reduce, or abolish 5-HT₂A engagement in living tissue.

What it cannot

The HTR is a motor reflex observed in a rodent. It reports nothing about subjective experience, perceptual change, or the quality of any effect a person would report. A compound can produce robust head twitches and still differ substantially from a classical psychedelic in its human effects.

Conversely, some compounds with recognised psychedelic activity in humans — ibogaine is a clear example — produce weak or inconsistent HTR, suggesting the assay does not capture all routes to altered states. A positive HTR is grounds for further investigation, not a characterisation of human risk or effect profile.

Results also do not transfer cleanly between species. The HTR is more robust in mice than in rats, and an absent rat HTR does not rule out 5-HT₂A agonism. A reader encountering a claim backed solely by HTR data should understand that it places a compound on the receptor map — it says nothing about the territory of human experience.